Document is current
Any future updates will be listed below
-
Authors
,
Heming, Nicholas
Berry, Lindsay
Lorenzi, Elizabeth
Hills, Thomas E.
Higgins, Alisa M.
Arabi, Yaseen
Aryal, Diptesh
Beane, Abigail
Best-Lane, Janis
Bonten, Marc
Bradbury, Charlotte
Brunkhorst, Frank
Burrell, Aidan
Buxton, Meredith
Cecconi, Maurizio
Chalmers, James D.
Cheng, Allen C.
Cooke, Graham
Cove, Matthew E.
Dark, Paul
Derde, Lennie
Detry, Michelle A.
Estcourt, Lise J.
Fitzgerald, Mark
Gordon, Anthony C.
Green, Cameron
Haniffa, Rashan
Hashmi, Madiha
Hays, Leanne
Horvat, Christopher
Huang, David T.
Ichihara, Nao
Jayakumar, Devachandran
Kruger, Peter S.
Lamontagne, Francois
Lawler, Patrick R.
Lewis, Roger J.
Litton, Edward
Marshall, John C.
McArthur, Colin J.
McAuley, Daniel F.
McGlothlin, Anna
McGuinness, Shay
McQuilten, Zoe
McVerry, Bryan J.
Morpeth, Susan C.
Mouncey, Paul R.
Nichol, Alistair D.
Parke, Rachael L.
Parker, Jane C.
Peters, Svenja
Ramnarayan, Padmanabhan
Reyes, Luis Felipe
Rowan, Kathryn M.
Saito, Hiroki
Santos, Marlene S.
Saunders, Christina T.
Seymour, Christopher
Shankar-Hari, Manu
Singh, Vanessa
Tambyah, Paul A.
Turgeon, Alexis F.
Turner, Anne M.
Ustianowski, Andrew
van de Veerdonk, Frank L.
Waite, Alicia A. C.
Whittaker, Elizabeth
Zarychanski, Ryan
Murthy, Srinivas
Webb, Steven A.
Berry, Scott
Venkatesh, Balasubramanian
Annane, Djillali
Angus, Derek C. https://orcid.org/0000-0002-7026-5181
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02735707 at ClinicalTrials.govDocuments that mention this clinical trial
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
https://doi.org/10.1136/bmjopen-2020-046799
Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial
https://doi.org/10.1136/bmj-2021-068407
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
https://doi.org/10.1007/s00134-021-06448-5
Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia
https://doi.org/10.1007/s00134-025-07861-w
Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review
https://doi.org/10.1136/openhrt-2021-001628
Drug treatments for covid-19: living systematic review and network meta-analysis
https://doi.org/10.1136/bmj.m2980
Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study
https://doi.org/10.1136/openhrt-2021-001785
- License Information
-
More Information
Article History
Received: 31 January 2025
Accepted: 9 March 2025
First Online: 22 April 2025
Declarations
:
: See submitted ICMJE forms for declared potential conflict of interests.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki Declaration and its later amendments.
: Informed consent was obtained before randomization from all patients or their surrogates, or in a deferred fashion, in accordance with local legislation.
